共 50 条
- [21] Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I StudyPLOS ONE, 2014, 9 (02):London, Cheryl A.Bernabe, Luis FeoBarnard, SandraKisseberth, William C.Borgatti, AntonellaHenson, MikeWilson, HeatherJensen, KierstenIto, DaisukeModiano, Jaime F.Bear, Misty D.Pennell, Michael L.Saint-Martin, Jean-RichardMcCauley, DilaraKauffman, MichaelShacham, Sharon
- [22] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study (vol 11, e0164646, 2016)PLOS ONE, 2019, 14 (01):Bekker, PirowDairaghi, DanielSeitz, LisaLeleti, ManmohanWang, YuErtl, LindaBaumgart, TrageenShugarts, SarahLohr, LisaDang, TonMiao, ShichangZeng, YibinFan, PingchenZhang, PenglieJohnson, DanielPowers, JayJaen, JuanCharo, IsraelSchall, Thomas J.
- [23] Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignanciesCANCER RESEARCH, 2024, 84 (06)Hannah, Alison L.Ritland, SteveSteele, ThomasSmith, StevenRam, AshwinSlingsby, B. T.Dhingra, KapilChrisman, JamesDua, RajeshTokunaga, YasunoriKono, ShigeyukiAga, Yasuhiro
- [24] ASNO03, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Rasco, Drew W.Sullivan, Ryan J.Lakhani, Nehal J.Reddy, SanjeevaRao, Niranjan SathyanarayanaDenis, Louis J.Tolcher, Anthony W.Flaherty, Keith
- [25] A highly selective Janus kinase 1 inhibitor, ivarmacitinib ointment, for the treatment of atopic dermatitis: results from a phase II studyBRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I52 - I53Li, BaopingGoh, Joshua S. H.Wang, DuoqinXu, JinhuaGoh, Aik Han
- [27] Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLLBLOOD, 2022, 140 : 2324 - 2325Blachly, James S.Stephens, Deborah M.Ye, J. ChristineLamanna, NicoleJain, NitinNiesman, MichaelZhang, KaiWoyach, Jennifer A.
- [28] Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative ColitisJOURNAL OF CROHNS & COLITIS, 2023, 17 : 938 - 938Klughammer, B.Piali, L.Nica, A. C.Nagel, S.Bailey, L.Jochum, C.Ignatenko, S.Blaeuer, A.Danilin, S.Gulati, P.Hayward, J.Scepanovic, P.Retout, S.Zhang, J. D.Bhosale, S.Sue-Ling, K.Chong, C. F.Christ, A.
- [29] PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Ahnert, Jordi RodonPerez, Cesar AugustoWong, Kit ManMaitland, Michael L.Tsai, FrankBerlin, JordanLiao, Kai HsinWang, I-MingMarkovtsova, LadaJacobs, Ira A.Cavazos, NoraLi, MengTolcher, Anthony W.
- [30] Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 studyCANCER RESEARCH, 2011, 71Musib, LunaEppler, SteveChoo, EdnaDeng, AlanMiles, DaleHsu, BihRosen, LeeSikic, BranimirLoRusso, PatriciaMa, WenGoldman, JonathanFisher, GeorgeWeise, AmyDy, GraceChan, IrisWare, Joseph